Therapeutic result of the use of HeberFERON® in patients with basal cell carcinoma in the face region

Abstract

Introduction: the introduction of HeberFERON® in the Cuban drug table as a therapeutic option for basal carcinoma is due to the successful and safe results of its use in any of its subtypes, sizes and locations. This avoids mutilations in the affected area.

Objective: to describe the therapeutic result of the use of intradermal perilesional HeberFERON® in the first patients with basal cell carcinoma in the facial region.

Methods: a descriptive cross-sectional study was carried out at the South Ciego de Ávila Community Polyclinic on the first 10 patients treated with the drug during 2018. The diagnosis of basal cell carcinoma was made based on clinical and histological criteria. The data were collected from the medical records of the patients. Ethical principles were met.

Results: all the patients had white skin (100,00 %). Skin phototype II (60,00 %), male sex (60,00  %), ages between 50 and 59 years (40,00 %), solid histological type (40,00 %), localization anatomical in the inner canthus of the eye (40,00 %) and the favorable response to complete treatment (80,00 %) predominated. Most of the adverse events were mild.

Conclusions: in eight of the first 10 patients treated, the favorable response to treatment was complete